Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A

Cell Cycle. 2010 Mar 1;9(5):901-8. doi: 10.4161/cc.9.5.10840. Epub 2010 Mar 3.

Abstract

Burkitt's lymphoma (BL) is characterized by translocation of the MYC gene to an immunoglobulin locus. Transgenic mouse models have been used to study the molecular changes that are necessary to bypass tumor suppression in the presence of translocated MYC. Inactivation of the p53 pathway is a major step to tumor formation in mouse models that is also seen in human disease. Human BL is often highly associated with Epstein-Barr virus (EBV). The EBV latency protein latent membrane protein 2A (LMP2A) is known to promote B cell survival by affecting levels of pro-survival factors. Using LMP2A transgenic mouse models, we have identified a novel mechanism that permits lymphomagenesis in the presence of an intact p53 pathway. This work uncovers a contribution of EBV to molecular events that have documented importance in BL pathogenesis, and may underlie the poorly understood link between EBV and BL.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Apoptosis
  • Burkitt Lymphoma / virology*
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / isolation & purification
  • Herpesvirus 4, Human / metabolism*
  • Humans
  • Mice
  • Mice, Transgenic
  • Proto-Oncogene Proteins c-myc / metabolism
  • Tumor Suppressor Protein p53 / metabolism
  • Viral Matrix Proteins / metabolism
  • Viral Matrix Proteins / physiology*

Substances

  • EBV-associated membrane antigen, Epstein-Barr virus
  • Proto-Oncogene Proteins c-myc
  • Tumor Suppressor Protein p53
  • Viral Matrix Proteins